
Velcade 3.5mg Injection
Marketer
Janssen Pharmaceuticals
Salt Composition
Bortezomib (3.5mg)
Overview Velcade 3.5mg Injection
Bortezomib 3.5mg injection is indicated for multiple myeloma and mantle cell lymphoma treatment. Its mechanism involves inhibiting or decelerating cancer cell proliferation. Administration is via injection by a qualified healthcare provider. Dosage and frequency are determined by your physician based on your condition and may be adjusted. Adhere strictly to your doctor's prescription; improper use or overdose can lead to severe adverse effects. Therapeutic benefits may take weeks or months to manifest; discontinue only under medical supervision. Common side effects include fatigue, nausea, vomiting, and decreased appetite. Increased fluid intake is often recommended. Operate machinery or drive only if alert, as drowsiness and dizziness may occur. This medication may reduce blood cell counts (red and white blood cells), increasing infection risk. Regular blood tests monitoring blood cell counts, along with heart, liver, and uric acid levels, are necessary. Prior to commencing treatment, disclose any liver, kidney, heart disease, or bleeding disorders to your doctor. Report cognitive symptoms like memory impairment or difficulty concentrating. Inform your healthcare team of all other medications you are taking, as interactions may occur. This medicine is contraindicated during pregnancy and breastfeeding; effective contraception is crucial for both partners. A patient support/assistance program in India is available through Tata 1mg; contact your physician or call (1800-102-1618) for further information.
Primary Ingredients of Velcade 3.5mg Injection
No text provided to rephrase.
Uses of Velcade 3.5mg Injection
Myeloma and mantle cell lymphoma
Major Benefits of Velcade 3.5mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Velcade 3.5mg Injection:
- Low blood platelets
- Fatigue
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Psychiatric disturbances
- Nausea
- Vomiting
- Loss of appetite
- Fever
- Anemia (low number of red blood cells)
- Diarrhea
- Decreased appetite
- Decreased white blood cell count (neutrophils)
- Constipation
How to use Velcade 3.5mg Injection:
This medication will be administered by your healthcare provider; self-medication is strongly discouraged.
How Velcade 3.5mg Injection works:
Bortezomib 3.5mg injection is a chemotherapeutic agent that inhibits proteasome function. This mechanism disrupts cellular protein regulation, causing an accumulation of proteins within malignant cells and ultimately triggering their demise.
SAFETY ADVICE
AlcoholUNSAFE
Using Velcade 3.5mg Injection concurrently with alcohol can result in significant sleepiness.
PregnancyCONSULT YOUR DOCTOR
Bortezomib 3.5mg injection poses a confirmed risk to a fetus and should not be administered during pregnancy. In exceptional circumstances involving life-threatening conditions, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is advised.
Breast feedingUNSAFE
Bortezomib 3.5mg injection is contraindicated for breastfeeding mothers. Evidence indicates potential infant toxicity from this medication.
DrivingUNSAFE
Administering Velcade 3.5mg Injection may result in adverse reactions impacting driving capabilities. These reactions can include fatigue, vertigo, syncope, or visual disturbances, potentially impairing driving ability.
KidneyCAUTION
Patients with significant kidney impairment should use Velcade 3.5mg Injection cautiously; dosage modification may be necessary. Physician consultation is advised.
LiverCAUTION
Patients with hepatic impairment should receive bortezomib 3.5 mg injection cautiously, potentially requiring dosage modification. Physician consultation is advised.
What if you forget to take Velcade 3.5mg Injection :
Omit a Velcade 3.5mg Injection dose? Seek your physician's advice.
Facts to Know About Velcade 3.5mg Injection
| Label | Value |
|---|---|
| Chemical Type | Phenylalanine-based Compounds |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
